Advicenne SA
PAR:ALDVI

Watchlist Manager
Advicenne SA Logo
Advicenne SA
PAR:ALDVI
Watchlist
Price: 1.798 EUR 6.26%
Market Cap: 25.6m EUR

Operating Margin

-167.1%
Current
Improving
by 148.9%
vs 3-y average of -316%

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-167.1%
=
Operating Income
€-4.6m
/
Revenue
€2.8m

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-167.1%
=
Operating Income
€-4.6m
/
Revenue
€2.8m

Peer Comparison

Country Company Market Cap Operating
Margin
FR
Advicenne SA
PAR:ALDVI
25.6m EUR
Loading...
US
Eli Lilly and Co
NYSE:LLY
982.2B USD
Loading...
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
Loading...
US
Johnson & Johnson
NYSE:JNJ
526.1B USD
Loading...
CH
Roche Holding AG
SIX:ROG
276.2B CHF
Loading...
UK
AstraZeneca PLC
LSE:AZN
215.4B GBP
Loading...
CH
Novartis AG
SIX:NOVN
221.7B CHF
Loading...
US
Merck & Co Inc
NYSE:MRK
270.7B USD
Loading...
DK
Novo Nordisk A/S
CSE:NOVO B
1.7T DKK
Loading...
IE
Endo International PLC
LSE:0Y5F
218B USD
Loading...
US
Pfizer Inc
NYSE:PFE
145.8B USD
Loading...
No Stocks Found

Market Distribution

Lower than 91% of companies in France
Percentile
9th
Based on 2 333 companies
9th percentile
-167.1%
Low
-17 526.7% — 1.3%
Typical Range
1.3% — 11.5%
High
11.5% — 89 700%
Distribution Statistics
France
Min -17 526.7%
30th Percentile 1.3%
Median 6.1%
70th Percentile 11.5%
Max 89 700%

Advicenne SA
Glance View

Market Cap
25.6m EUR
Industry
Pharmaceuticals

Advicenne SA is a pharmaceutical company, which engages in the development of innovative treatments in Nephrology. The company is headquartered in Nimes, Occitanie and currently employs 30 full-time employees. The company went IPO on 2017-12-06. The firm focuses on the development of paediatric friendly therapeutics for the treatment of orphan renal diseases and niche neurology indications. The Company’s medicines are developed for patients of all ages in the fields of nephrology and neurology. Its lead product includes ADV7103, which is in phase III, designed to address dRTA both in children for whom the disease is genetic as well as for adults who may have acquired the condition as a result of autoimmune disease. Apart from its lead product, the Company also develops a portfolio of products, including ADV6209, which is an oral liquid solution for moderate sedation; Likozam, which is designed to meet the unmet medical need of patients with partial and generalized chronic refractory epilepsy; Levidcen, which is used to address the unmet medical need of epileptic patients with partial onset seizures, and ADV7103 Cystinuria, among others.

ALDVI Intrinsic Value
HIDDEN
Show
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
-167.1%
=
Operating Income
€-4.6m
/
Revenue
€2.8m
What is Advicenne SA's current Operating Margin?

The current Operating Margin for Advicenne SA is -167.1%, which is above its 3-year median of -316%.

How has Operating Margin changed over time?

Over the last 3 years, Advicenne SA’s Operating Margin has increased from -325.4% to -167.1%. During this period, it reached a low of -432.1% on Dec 31, 2022 and a high of -167.1% on Jul 30, 2025.

Back to Top